Magdalena Biosciences, Inc.
Joint venture founded to discover and develop pharmaceutical-grade botanical drug candidates for neuropsychiatric indications. The company holds an exclusive license to a characterized library of medicinal plants and extracts and focuses on accelerating development of IND-enabled botanical medicines (claimed pathway from plant collection to initiation of human proof-of-concept studies in 12–24 months). Initial therapeutic focus includes treatments for executive dysfunction in ADHD and cognitive deficits in schizophrenia.
Industries
N/A
Nr. of Employees
small (1-50)
Magdalena Biosciences, Inc.
8 The Green, Suite #8637, Dover, DE 19901
Products
Botanical drug candidate for cognitive deficits in schizophrenia (first botanical candidate)
Pharmaceutical-grade botanical drug candidate advanced for treatment of cognitive deficits associated with schizophrenia; part of the company's IND-enabled pipeline.
Pipeline of IND-enabled botanical drug candidates (ADHD, schizophrenia, anxiety, depression)
Multiple botanical candidates in development intended to address executive dysfunction in ADHD and cognitive/positive/negative symptoms in schizophrenia, as well as anxiety and depression.
Botanical drug candidate for cognitive deficits in schizophrenia (first botanical candidate)
Pharmaceutical-grade botanical drug candidate advanced for treatment of cognitive deficits associated with schizophrenia; part of the company's IND-enabled pipeline.
Pipeline of IND-enabled botanical drug candidates (ADHD, schizophrenia, anxiety, depression)
Multiple botanical candidates in development intended to address executive dysfunction in ADHD and cognitive/positive/negative symptoms in schizophrenia, as well as anxiety and depression.
Services
Discovery and development of pharmaceutical-grade botanical drug candidates from a curated medicinal plant library for neuropsychiatric indications.
Conducting preclinical studies to evaluate psychoactive activity and mechanisms of action for plant-derived candidates.
Preparation of IND-enabling data packages and alignment with FDA Botanical Drug Guidance toward potential clinical trials and regulatory submissions.
Field collection coordination, sustainable sourcing practices and establishment of access and benefit-sharing agreements for research materials.
Discovery and development of pharmaceutical-grade botanical drug candidates from a curated medicinal plant library for neuropsychiatric indications.
Conducting preclinical studies to evaluate psychoactive activity and mechanisms of action for plant-derived candidates.
Preparation of IND-enabling data packages and alignment with FDA Botanical Drug Guidance toward potential clinical trials and regulatory submissions.
Field collection coordination, sustainable sourcing practices and establishment of access and benefit-sharing agreements for research materials.
Expertise Areas
- Botanical drug development
- Ethnobotany and sustainable sourcing
- Preclinical pharmacology for CNS/psychiatric indications
- Clinical proof-of-concept initiation and trial planning
Key Technologies
- Phytochemical extraction and purification
- Botanical standardization and characterization
- Preclinical animal and in vitro pharmacology models (CNS/psychiatric)
- Clinical proof-of-concept trial execution
News & Updates
Announcement of authorization of an access and benefit-sharing agreement to support research into potential mental health and CNS indications using coca.
Study report indicating psychoactive activity of a medicinal plant used historically by indigenous peoples; presented as evidence relevant to the joint venture's research.
Announcement of initiation of preclinical studies to evaluate plant extracts for depression, anxiety, ADHD and other mental health indications.
Announcement of an out-license deal between Jaguar Health and the joint venture for a botanical drug candidate targeting schizophrenia.
Announcement of importation of coca leaf from Peru by the joint venture for research purposes related to mental health indications.
Announcement of authorization of an access and benefit-sharing agreement to support research into potential mental health and CNS indications using coca.
Study report indicating psychoactive activity of a medicinal plant used historically by indigenous peoples; presented as evidence relevant to the joint venture's research.
Announcement of initiation of preclinical studies to evaluate plant extracts for depression, anxiety, ADHD and other mental health indications.
Announcement of an out-license deal between Jaguar Health and the joint venture for a botanical drug candidate targeting schizophrenia.
Announcement of importation of coca leaf from Peru by the joint venture for research purposes related to mental health indications.